According to a new report, published by KBV research, The Global Allergy Immunotherapy Market size is expected to reach $2.9 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period.
The Hospital Pharmacy segment is showcasing a CAGR of 8.5% during (2023 - 2030). This is due to the increase in the number of patients seeking treatment for allergic diseases and the global hospitalization rate. Typically, allergy injections are administered at medical facilities or doctor's offices to track and manage any adverse effects. Thus, the segment expansion is further accelerated.
The Subcutaneous Immunotherapy (SCIT) segment is leading the Global Allergy Immunotherapy Market by Treatment Type in 2022; thereby, achieving a market value of $1.9 billion by 2030. The most efficient and popular type of allergen immunotherapy is SCIT. This therapy can treat asthma, stinging insect hypersensitivity, and allergic rhinitis effectively. Additionally, SCIT has shown success in managing a variety of allergens. Because of this, SCIT is used extensively than SLIT.
The Allergic Asthma segment is exhibiting a CAGR of 8.2% during (2023 - 2030). Allergy-related asthma is a respiratory disorder that results from allergies. The disorder known as allergic asthma causes the airways to constrict when one inhales an allergen. Pollen, dander, or mold spores are common airborne contaminants that could cause asthma. Feeling out of breath, frequent coughing, and other symptoms of asthma.
The Europe region dominated the Global Allergy Immunotherapy Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The North America region is exhibiting a CAGR of 8.1% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 9.4% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/allergy-immunotherapy-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
By Distribution Channel
By Treatment Type
By Allergy Type
By Geography
Companies Profiled
Unique Offerings 
